Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Christine N. Spencer(The University of Texas MD Anderson Cancer Center), Jennifer L. McQuade(The University of Texas MD Anderson Cancer Center), Vancheswaran Gopalakrishnan(The University of Texas MD Anderson Cancer Center), John A. McCulloch(National Cancer Institute), Marie Vétizou(National Cancer Institute), Alexandria P. Cogdill(The University of Texas MD Anderson Cancer Center), Md Abdul Wadud Khan(The University of Texas MD Anderson Cancer Center), Xiaotao Zhang(The University of Texas MD Anderson Cancer Center), Michael G. White(The University of Texas MD Anderson Cancer Center), Christine B. Peterson(The University of Texas MD Anderson Cancer Center), Matthew C. Wong(The University of Texas MD Anderson Cancer Center), Golnaz Morad(The University of Texas MD Anderson Cancer Center), Theresa Rodgers(The University of Texas MD Anderson Cancer Center), Jonathan H. Badger(National Cancer Institute), Beth A. Helmink(The University of Texas MD Anderson Cancer Center), Miles C. Andrews(The University of Texas MD Anderson Cancer Center), Richard R. Rodrigues(Center for Cancer Research), Andrey Morgun(Oregon State University), Young S. Kim(Prevention Group), Jason Roszik(The University of Texas MD Anderson Cancer Center), Kristi L. Hoffman(Baylor College of Medicine), Jiali Zheng(The University of Texas MD Anderson Cancer Center), Yifan Zhou(The University of Texas MD Anderson Cancer Center), Yusra B. Medik(The University of Texas MD Anderson Cancer Center), Laura M. Kahn(The University of Texas MD Anderson Cancer Center), Sarah B. Johnson(The University of Texas MD Anderson Cancer Center), Courtney W. Hudgens(The University of Texas MD Anderson Cancer Center), Khalida Wani(The University of Texas MD Anderson Cancer Center), Pierre-Olivier Gaudreau(Queen's University), Angela L. Harris(The University of Texas MD Anderson Cancer Center), Mohamed A. Jamal(The University of Texas MD Anderson Cancer Center), Erez N. Baruch(The University of Texas Health Science Center at Houston), Eva Pérez‐Guijarro, Chi‐Ping Day, Glenn Merlino, Barbara Pazdrak(The University of Texas MD Anderson Cancer Center), Brooke S. Lochmann(The University of Texas MD Anderson Cancer Center), Robert Szczepaniak‐Sloane(The University of Texas MD Anderson Cancer Center), Reetakshi Arora(The University of Texas MD Anderson Cancer Center), Jaime Anderson(The University of Texas MD Anderson Cancer Center), Chrystia M. Zobniw(The University of Texas MD Anderson Cancer Center), Eliza Posada(The University of Texas MD Anderson Cancer Center), Elizabeth Sirmans(The University of Texas MD Anderson Cancer Center), Julie M. Simon(The University of Texas MD Anderson Cancer Center), Lauren E. Haydu(The University of Texas MD Anderson Cancer Center), Elizabeth M. Burton(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), Minghao Dang(The University of Texas MD Anderson Cancer Center), Karen Clise-Dwyer(The University of Texas MD Anderson Cancer Center), Sarah Schneider(The University of Texas MD Anderson Cancer Center), Thomas Chapman(The University of Texas MD Anderson Cancer Center), Nana-Ama A.S. Anang(The University of Texas MD Anderson Cancer Center), Sheila Duncan(The University of Texas MD Anderson Cancer Center), Joseph Toker(University of Cambridge), Jared Malke(The University of Texas MD Anderson Cancer Center), Isabella C. Glitza(The University of Texas MD Anderson Cancer Center), Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Adi Diab(The University of Texas MD Anderson Cancer Center), Michael K. Wong(The University of Texas MD Anderson Cancer Center), Sapna P. Patel(The University of Texas MD Anderson Cancer Center), Scott E. Woodman(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Merrick I. Ross(The University of Texas MD Anderson Cancer Center), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Jeffrey E. Lee(The University of Texas MD Anderson Cancer Center), Patrick Hwu(The University of Texas MD Anderson Cancer Center), V. Behrana Jensen(The University of Texas MD Anderson Cancer Center), Yardena Samuels(Weizmann Institute of Science), Ravid Straussman(Weizmann Institute of Science), Nadim J. Ajami(The University of Texas MD Anderson Cancer Center), Kelly C. Nelson(The University of Texas MD Anderson Cancer Center), Luigi Nezi(Institute for Experimental Endocrinology and Oncology), Joseph F. Petrosino(Baylor College of Medicine), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Jianhua Hu(Columbia University), Robert R. Jenq(The University of Texas MD Anderson Cancer Center), Michael T. Tetzlaff(University of California, San Francisco), Yan Yan(Harvard University), Wendy S. Garrett(Harvard University), Curtis Huttenhower(Broad Institute), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), Stephanie S. Watowich(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center), Lorenzo Cohen(The University of Texas MD Anderson Cancer Center), Giorgio Trinchieri(National Cancer Institute), Carrie R. Daniel(The University of Texas MD Anderson Cancer Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center)
Cited by 868Open Access
Abstract
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer, but the effect of diet and supplements on this interaction is not well studied. We assessed fecal microbiota profiles, dietary habits, and commercially available probiotic supplement use in melanoma patients and performed parallel preclinical studies. Higher dietary fiber was associated with significantly improved progression-free survival in 128 patients on ICB, with the most pronounced benefit observed in patients with sufficient dietary fiber intake and no probiotic use. Findings were recapitulated in preclinical models, which demonstrated impaired treatment response to anti–programmed cell death 1 (anti–PD-1)–based therapy in mice receiving a low-fiber diet or probiotics, with a lower frequency of interferon-γ–positive cytotoxic T cells in the tumor microenvironment. Together, these data have clinical implications for patients receiving ICB for cancer.
Related Papers
No related papers found
Powered by citation graph analysis